Literature DB >> 18378538

Managing vesicant extravasations.

Lisa Schulmeister1.   

Abstract

Extravasation is an unusual but potentially severe complication of vesicant chemotherapy administration. Some extravasation injuries prompt litigation and the oncologist's actions, or lack of action, are scrutinized in the courtroom. This article presents advice and recommendations for treating patients who receive vesicants and includes a discussion of FDA-approved vesicant extravasation treatments and antidotes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378538     DOI: 10.1634/theoncologist.2007-0191

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  6 in total

Review 1.  Non-invasive delivery strategies for biologics.

Authors:  Aaron C Anselmo; Yatin Gokarn; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2018-11-30       Impact factor: 84.694

2.  Screening of the chemoprotective effect of 13 compounds and their mixtures with sodium 2-mercaptoethanesulfonate against 2-chloroethyl ethyl sulfide.

Authors:  Petr Jost; Jaroslav Pejchal; Tomas Kucera; Lubica Muckova; Rudolf Stetina
Journal:  J Appl Biomed       Date:  2019-06-17       Impact factor: 1.797

Review 3.  Extravasation of antineoplastic agents: prevention and treatments.

Authors:  Rita Boschi; Elena Rostagno
Journal:  Pediatr Rep       Date:  2012-08-01

4.  Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report.

Authors:  Gaetano Di Costanzo; Giovanna Loquercio; Gianpaolo Marcacci; Vincenzo Iervolino; Stefano Mori; Arnolfo Petruzziello; Pasquale Barra; Carmela Cacciapuoti
Journal:  Onco Targets Ther       Date:  2015-02-09       Impact factor: 4.147

5.  Treatment of cutaneous injuries of neonates induced by drug extravasation with hyaluronidase and hirudoid.

Authors:  Ya-Min Yan; Qiao-Ling Fan; Ai-Qiu Li; Jia-Ling Chen; Fei-Fei Dong; Mei Gong
Journal:  Iran J Pediatr       Date:  2014-07-03       Impact factor: 0.364

6.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.